Pathogenesis of Ovarian Serous Carcinoma as the Basis for Immunologic Directed Diagnosis and Treatment. Project 3 - Development of Antigen-Specific Cancer Vaccines for the Control of Ovarian Cancer
Abstract
The purpose of this study is to test whether the greater extent of intracellular spreading of encoded antigen will generate a higher degree of antigen-specific immunity and ant-tumor effects in vaccinated mice. We previously showed that DNA vaccine of HVP22 linkage with to a model antigen, E7 generates strong CD8 specific T cell response and anti-tumor effects. We generated a DNA vaccines encoding BVP22 and MDV-I VP22 linked with E7, respectively in this report. We demonstrated that compared with mice vaccinated with DNA encoding wild-type E7, mice vaccinated with BVP22/E7 and MDV-1 VP22/E7 DNA exhibited a significant increase in number of E7-specific CD8+-T-cell precursors as well as stronger anti-tumor effects. Furthermore, our data indicated that the anti-tumor effect was CD8 dependent. These results suggested that the development of vaccines encoding VP22 fused to a target antigen might be a promising strategy for improving DNA vaccine potency.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2003
- Accession Number
- ADA420909
Entities
People
- Robert J. Kurman
- T. C. Wu
Organizations
- Johns Hopkins University